Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: sodium hydroxide; water for injections; lactic acid; sorbitol - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: sorbitol; lactic acid; water for injections; sodium hydroxide - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - irinotecan hydrochloride trihydrate 20 mg/ml;  ;   - solution for injection - 20 mg/ml - active: irinotecan hydrochloride trihydrate 20 mg/ml     excipient: hydrochloric acid lactic acid sodium hydroxide sorbitol water for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: lactic acid; sodium hydroxide; sorbitol; water for injections - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - irinotecan hydrochloride trihydrate 20 mg/ml - concentrate for solution for infusion - 20 mg/ml - irinotecan hydrochloride trihydrate 20 mg/ml - topoisomerase 1 (top1) inhibitors

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - irinotecan hydrochloride trihydrate 20 mg/ml - concentrate for solution for infusion - 20 mg/ml - irinotecan hydrochloride trihydrate 20 mg/ml - topoisomerase 1 (top1) inhibitors

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - irinotecan hydrochloride trihydrate 20 mg/ml - concentrate for solution for infusion - 20 mg/ml - irinotecan hydrochloride trihydrate 20 mg/ml - topoisomerase 1 (top1) inhibitors